Development and validation of a novel chiral chromatographic method for separation of lenalidomide enantiomers in human plasma.
Chirality
; 35(2): 83-91, 2023 02.
Article
em En
| MEDLINE
| ID: mdl-36458987
ABSTRACT
Lenalidomide (LND) is an analogue of thalidomide that is second generation immunomodulatory drugs (IMiDs). LND contains asymmetric carbon atom and exist R and S enantiomer. S (-) form of enantiomer are considered to be more potent and biologically active in tumor cell. It is available in racemic form for clinical use. The study aims to develop and validate enantiomer separation of LND in human plasma. The chromatographic enantiomeric separation was achieved on a Daicel-CSP, Chiralpack IA 4.6 × 250 mm_5 µm. The mobile phase was constituted in combination of methanolglacial acetic acid at a concentration of 499.50 ml 50 µl. UV wavelength detection was 220 nm. The RSD% for all validation parameters was found to be within the acceptable limit. The chiral chromatographic (chiral stationary phase-high-performance liquid chromatography [CSP-HPLC]) method developed and validated for the quantitative estimation of LND enantiomers S (-) and R (+) in human plasma sample is accurate, precise, robust, stable and selective.
Palavras-chave
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Talidomida
Limite:
Humans
Idioma:
En
Ano de publicação:
2023
Tipo de documento:
Article